Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michail Vikelis

Showing results (51-60 of 68) with videos related to

Pageof 7
Sort By:
Journal of Clinical Medicine|May 25, 2024
Results of a Web-Based Survey on 2565 Greek Migraine Patients in 2023: Demographic Data, Imposed Burden and Satisfaction to Acute and Prophylactic Treatments in the Era of New Treatment OptionsEmmanouil V Dermitzakis, Andreas A Argyriou, Konstantinos Bilias, et al.
Frontiers in Neurology|January 26, 2023
Variability in oxidative stress-related genes (<i>SOD2, CAT, GPX1, GSTP1, NOS3, NFE2L2</i>, and <i>UCP2</i>) and susceptibility to migraine clinical phenotypes and featuresMaria Papasavva, Michail Vikelis, Vasileios Siokas, et al.
Journal of Molecular Neuroscience : MN|September 27, 2021
Evidence That HFE H63D Variant Is a Potential Disease Modifier in Cluster HeadacheMaria Papasavva, Michail Vikelis, Martha-Spyridoula Katsarou, et al.
Expert Review of Neurotherapeutics|September 16, 2024
Menopause and its impact on the effectiveness of fremanezumab for migraine prophylaxis: post-hoc analysis of a prospective, real-world Greek registryAndreas A Argyriou, Emmanouil V Dermitzakis, Georgia Xiromerisiou, et al.
Advances in Therapy|March 10, 2023
A Prospective, Observational Study Assessing Effectiveness, Safety, and QoL of Greek Patients with Multiple Sclerosis Under Treatment with FingolimodDimos D Mitsikostas, Anastasios Orologas, Efthimios Dardiotis, et al.
Medicina (Kaunas, Lithuania)|April 28, 2023
A Survey of Greek Primary Care Physicians on Their Likeability in Treating Migraines and Other Common DiseasesMichail Vikelis, Andreas A Argyriou, Anastasia Antoniou, et al.
Frontiers in Neurology|March 11, 2025
The unmet needs in management, the treatment gap and the burden of migraine in Greece: a Delphi consensus and focus group study from patients' perspectiveMichail Vikelis, Georgia Kourlaba, Lia Barba, et al.
Brain Sciences|January 8, 2025
Real-World Open-Label Experience with Rimegepant for the Acute Treatment of Migraine Attacks: A Multicenter Pilot StudyEmmanouil V Dermitzakis, Dimitrios Rikos, Michail Vikelis, et al.
Cephalalgia : an International Journal of Headache|June 4, 2026
Achieving International Headache Society-aspired optimal migraine control in fremanezumab-treated patients: A post-hoc analysis of a real-world, prospective study from the GRASP study groupAndreas A Argyriou, Emmanouil V Dermitzakis, Dimitrios Rikos, et al.
European Journal of Neurology|August 14, 2025
Effects of Pausing and Re-Initiating Fremanezumab After Continuous 24-Month Treatment for Preventing Difficult-To-Treat Migraine: Prospective, Multicenter, Real-World Data From the GRASP Study GroupAndreas A Argyriou, Emmanouil V Dermitzakis, Georgia Xiromerisiou, et al.
Pageof 7

Showing results (51-60 of 68) with videos related to

Sort By:
Pageof 7
Journal of Clinical Medicine|May 25, 2024
Results of a Web-Based Survey on 2565 Greek Migraine Patients in 2023: Demographic Data, Imposed Burden and Satisfaction to Acute and Prophylactic Treatments in the Era of New Treatment OptionsEmmanouil V Dermitzakis, Andreas A Argyriou, Konstantinos Bilias, et al.
Frontiers in Neurology|January 26, 2023
Variability in oxidative stress-related genes (<i>SOD2, CAT, GPX1, GSTP1, NOS3, NFE2L2</i>, and <i>UCP2</i>) and susceptibility to migraine clinical phenotypes and featuresMaria Papasavva, Michail Vikelis, Vasileios Siokas, et al.
Journal of Molecular Neuroscience : MN|September 27, 2021
Evidence That HFE H63D Variant Is a Potential Disease Modifier in Cluster HeadacheMaria Papasavva, Michail Vikelis, Martha-Spyridoula Katsarou, et al.
Expert Review of Neurotherapeutics|September 16, 2024
Menopause and its impact on the effectiveness of fremanezumab for migraine prophylaxis: post-hoc analysis of a prospective, real-world Greek registryAndreas A Argyriou, Emmanouil V Dermitzakis, Georgia Xiromerisiou, et al.
Advances in Therapy|March 10, 2023
A Prospective, Observational Study Assessing Effectiveness, Safety, and QoL of Greek Patients with Multiple Sclerosis Under Treatment with FingolimodDimos D Mitsikostas, Anastasios Orologas, Efthimios Dardiotis, et al.
Medicina (Kaunas, Lithuania)|April 28, 2023
A Survey of Greek Primary Care Physicians on Their Likeability in Treating Migraines and Other Common DiseasesMichail Vikelis, Andreas A Argyriou, Anastasia Antoniou, et al.
Frontiers in Neurology|March 11, 2025
The unmet needs in management, the treatment gap and the burden of migraine in Greece: a Delphi consensus and focus group study from patients' perspectiveMichail Vikelis, Georgia Kourlaba, Lia Barba, et al.
Brain Sciences|January 8, 2025
Real-World Open-Label Experience with Rimegepant for the Acute Treatment of Migraine Attacks: A Multicenter Pilot StudyEmmanouil V Dermitzakis, Dimitrios Rikos, Michail Vikelis, et al.
Cephalalgia : an International Journal of Headache|June 4, 2026
Achieving International Headache Society-aspired optimal migraine control in fremanezumab-treated patients: A post-hoc analysis of a real-world, prospective study from the GRASP study groupAndreas A Argyriou, Emmanouil V Dermitzakis, Dimitrios Rikos, et al.
European Journal of Neurology|August 14, 2025
Effects of Pausing and Re-Initiating Fremanezumab After Continuous 24-Month Treatment for Preventing Difficult-To-Treat Migraine: Prospective, Multicenter, Real-World Data From the GRASP Study GroupAndreas A Argyriou, Emmanouil V Dermitzakis, Georgia Xiromerisiou, et al.
Pageof 7